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Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary
tract infections
Abstract
Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being utilized. Its dosing
convenience renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favour its
use against complicated urinary tract infections (cUTIs). Despite this, sufficient clinical data are lacking
for its use against cUTIs in the outpatient setting. We assessed the microbiological and clinical cure rates
associated with ertapenem treatment for cUTIs in two outpatient parenteral antimicrobial therapy (OPAT)
departments. Methods: We undertook a prospective observational study of adult patients who received
ertapenem for cUTIs between August 2010 and August 2014. Data on patient characteristics, clinical
progress and microbiological results were collected and analysed. Results: Sixty-one patients were
enrolled. The median age was 59 years (range 24, 83) and 61% were male. The most common diagnoses
were pyelonephritis (39%) and prostatitis (15%). The most common causative organism was Escherichia
coli (67%). Extended-spectrum β-lactamase (ESBL)-producing organisms were detected in 72% of
infections. Microbiological cure was achieved in 67% overall, and was less likely in those with Klebsiella
pneumoniae infection (OR = 0.21 [95%CI: 0.05 to 0.85] p = 0.029). Clinical cure was observed in 92% of
patients. Conclusion: In this study of treating cUTIs with ertapenem, we have demonstrated good clinical
outcomes. A lower than expected microbiological cure rate was observed in those with Klebsiella
pneumoniae infection.
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Abstract:

Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being
utilised. Its dosing convenience renders it suitable for outpatient therapy, and its
pharmacokinetic characteristics favor its use against complicated urinary tract
infections (cUTIs). Despite this, sufficient clinical data are lacking for its use against
cUTIs in the outpatient setting. We assessed the microbiologic and clinical cure rates
associated with ertapenem treatment for cUTIs in two outpatient parenteral
antimicrobial therapy (OPAT) departments.
Methods: We undertook a prospective observational study of adult patients who
received ertapenem for cUTIs between August 2010 and August 2014. Data on patient
characteristics, clinical progress, and microbiological results were collected and
analysed.
Results: 61 patients were enrolled. The median age was 59 years (range 24, 83) and
61% were male. The most common diagnoses were pyelonephritis (39%) and
prostatitis (15%). The most common causative organism was Escherichia coli (67%).
ESBL-producing organisms were detected in 72% of infections. Microbiologic cure was
achieved in 67% overall, and was less likely in those with Klebsiella pneumoniae
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infection (OR=0.21 [95%CI: 0.05 to 0.85] p=0.029). Clinical cure was observed in 92%
of patients.
Conclusion: In this study of treating cUTIs with ertapenem, we have demonstrated
good clinical outcomes. A lower than expected microbiologic cure rates was observed
in those with Klebsiella pneumoniae infection.
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Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections

3

ABSTRACT:

4

Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being utilised. Its dosing convenience

5

renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favor its use against complicated

6

urinary tract infections (cUTIs). Despite this, sufficient clinical data are lacking for its use against cUTIs in the

7

outpatient setting. We assessed the microbiologic and clinical cure rates associated with ertapenem treatment for

8

cUTIs in two outpatient parenteral antimicrobial therapy (OPAT) departments.

9

Methods: We undertook a prospective observational study of adult patients who received ertapenem for cUTIs

10

between August 2010 and August 2014. Data on patient characteristics, clinical progress, and microbiological

11

results were collected and analysed.

12

Results: 61 patients were enrolled. The median age was 59 years (range 24, 83) and 61% were male. The most

13

common diagnoses were pyelonephritis (39%) and prostatitis (15%). The most common causative organism was

14

Escherichia coli (67%). ESBL-producing organisms were detected in 72% of infections. Microbiologic cure was

15

achieved in 67% overall, and was less likely in those with Klebsiella pneumoniae infection (OR=0.21 [95%CI:

16

0.05 to 0.85] p=0.029). Clinical cure was observed in 92% of patients.

17

Conclusion: In this study of treating cUTIs with ertapenem, we have demonstrated good clinical outcomes. A

18

lower than expected microbiologic cure rates was observed in those with Klebsiella pneumoniae infection.

19
20

KEYWORDS: Complicated Urinary Tract Infections; Outpatient Parenteral Antimicrobial Therapy; Ertapenem;

21

Multi-Drug Resistant Organisms.

22

1. Introduction:

23

Complicated urinary tract infections (cUTIs) occur in those with a functionally, metabolically, or anatomically

24

abnormal urinary tract, in addition to catheterised patients[1]. The clinical spectrum ranges from mild cystitis to

25

life-threatening sepsis. Management of UTIs includes the use of a variety of broad-spectrum antimicrobials[2].

26

Recently, emerging resistance mechanisms have rendered common antimicrobial agents less effective. Current

27

practice recommends 10 to 14 days of therapy with an antimicrobial agent active against a wide range of gram-

28

negative bacilli[2]. With the changing epidemiology of extended-spectrum β-lactamase (ESBL) producing

29

organisms, the antibiotic options will be increasingly limited, rendering carbapenems as the treatment of choice for

30

serious infections due to ESBL-producing organisms[3].

31

Ertapenem has excellent antimicrobial activity against a broad spectrum of pathogens associated with hospital and

32

community-acquired infections, including ESBL producing gram negative organisms, which are commonly

33

implicated in UTIs[4]. It has narrower activity compared with other carbapenems, and has a low minimum

34

inhibitory concentration (MIC) against ESBL producing organisms rendering it an effective first line agent[5].

35

Furthermore, its excretion in the urine gives it a favourable pharmacokinetic profile to treat cUTIs[6]. In a well-

36

designed study, ertapenem was found to be as efficacious as ceftriaxone in treating a cohort of cUTIs with non-

37

ESBL producing gram negatives[7].

38

In the outpatient setting, there are few studies on cohorts of patients with cUTIs caused by ESBL producing gram-

39

negative organisms[8-10]. Given that ertapenem can be administered once daily it is suitable for use in outpatient

40

therapy. Treating infections in the outpatient setting has been proven cost effective and safe[11]. Hence, we

41

conducted this study to establish the efficacy of ertapenem in treating cUTIs in the outpatient setting.

42

2. Methods:

43

We undertook a prospective, open-label, observational study through two of Singapore’s largest outpatient

44

parenteral antimicrobial therapy (OPAT) centres over a 4-year period. Eligible patients were those that were

45

prescribed intravenous (IV) ertapenem 1g, or a renally adjusted dose, every 24 hours as outpatients (either initially

46

as inpatients or for the full duration). Our study was approved by the Institutional Review Board covering both

47

hospitals.

48

Inclusion criteria included non-pregnant adult patients greater than 21 years of age with cUTI as defined by Rubin

49

et al, [12] due to a pathogen susceptible to ertapenem isolated in urine or blood, and those with favourable clinical

50

response to initial therapy in hospital, where applicable. Patients with hypersensitivity reactions to ertapenem or in

51

whom an informed consent could not be obtained were excluded.

52

As an observational study the investigators had no input into the duration of treatment. Patients were monitored

53

daily at the OPAT centre. This included clinical assessment for improvement of presenting complaints and

54

potential adverse events. Serum creatinine, electrolytes and white blood cell count, and urinalysis were performed

55

routinely or when clinically indicated. Mid-stream urine cultures were performed on the last day of therapy (± 3

56

days). After completion of treatment, patients were assessed by an infectious diseases physician at 30 days (± 7

57

days) with repeat urinalysis and mid-stream urine culture.

58

The primary outcome of the study was microbiological cure, which was defined as a negative culture on any

59

occasion after treatment. Those with the same organism isolated any time following therapy were considered as

60

persistent infection, and those who developed a new microorganism were considered as having a superinfection,

61

regardless of whether they developed symptoms. The secondary outcome of the study was clinical cure defined as

62

complete resolution of symptoms and signs at diagnosis. Outcome was assessed as therapy success or failure.

63

Failure was defined as developing adverse outcomes in addition to change of therapy, hospital re-admission due to

64

cUTI and mortality.

65

Bacteria were identified by matrix associated laser desorption ionization time of flight mass spectrometry

66

(MALDI-TOF-MS, Bruker Daltoniks GmHB, Bremen, Germany). Antibiotic susceptibility was determined using

67

VITEK II (bioMerieux S.A., Marcy l’Etoile, France), and interpreted using breakpoints according to EUCAST..

68

For descriptive analysis, the means and their standard deviation (SD), or medians with their range were reported.

69

Chi-square or Fisher’s exact tests were used to compare categorical variables; t-test and Mann–Whitney tests to

70

compare continuous variables. A multivariate logistic regression model with variables in univariate analysis at a P

71

< 0.2 level was constructed. Using backward selection, variables were retained in the final logistic regression

72

model if their significance remained below P = 0.2. All tests were conducted at the 5% level of significance, with

73

odds ratios (OR) and corresponding 95% confidence intervals (CI) reported. All statistical analyses were

74

performed using Stata 9.0 (Stata Corp., College Station, TX, 2005).

75

3. Results and data analysis:

76

A total of 61 patients were studied. Baseline demographic features and disease characteristics are summarised in

77

Table 1. Of the patients 61% were male, and ethnic diversity represented that of Singapore with 62% being of

78

Chinese ethnicity. Of all patients 24 (39.3%) had pyelonephritis and 11 (18%) had prostatitis. Six (9.8%) had

79

associated bacteraemia and were classified as urosepsis, and 20 (32.8%) had a diagnosis of cystitis. The duration

80

of treatment in the outpatient setting was of a mean of 10 days (SD= +/-7.5). The total duration of therapy

81

including inpatient and outpatient therapy was of a mean of 22 days (SD= +/-11.8).

82

Frequently isolated pathogens were Escherichia coli and Klebsiella pneumoniae, recovered from 41 (67.2%) and

83

14 (23%) respectively. Other cases demonstrated both E.coli and K. pneumoniae (3 patients), Morganella

84

morganii (2 patients) and 1 had negative cultures (clinical diagnosis as pyelonephritis). All isolates were

85

susceptible to ertapenem. Out of 60 isolates, 41 (68%) were ESBL producers. Twenty-seven (66%) of the E.coli

86

isolates and 12 (86%) of the K. pneumoniae isolates were ESBL-positive (Table 2).

87

Five patients discontinued therapy early, one due to clinical treatment failure, another for persistent symptoms with

88

additional therapy added and 3 due to adverse reactions. All those completing treatment had a follow up culture

89

undertaken a median time of 30 days (range: 4-40) after cessation of ertapenem. Forty-one (68%) had

90

microbiological eradication, 9 (15%) had persistence of the infecting bacteria, and 11 (18%) had a different

91

organism isolated. Nine out of those 11 had total resolution of symptoms (Table 3). Clinical cure was obtained in

92

56 (92%) having complete resolution of signs and symptoms. Only 1 (2%) had no improvement in symptoms and

93

had additional therapy. Three (5%) developed adverse drug reactions attributable to ertapenem. One stopped

94

treatment on day 5 of therapy due to rash, but had microbiological eradication and resolution of signs and

95

symptoms. Two others developed headache and vomiting, and were switched to alternative therapy.

96

There were 40 (65%) patients who achieved both clinical cure and microbiological eradication, while 9 (15%) had

97

a clinical cure with a different organism cultured, and 7 (11%) had the same organism isolated but with clinical

98

cure achieved. Only 2 (3%) were classified as microbiological persistence with clinical failure.

99

Multivariate logistic regression showed that having an infection with K. pneumoniae at baseline was found to be a

100

risk factor for not achieving microbiological cure (OR=0.21 [95%CI: 0.05 to 0.85] p=0.029). Compared with other

101

ethnicities, Indians were more likely to achieve microbiological failure(OR=4.47 [95%CI: 1.06 to 18.9] p= 0.042).

102

There were no risk factors identified for not achieving clinical cure on univariate analysis, and hence a multivariate

103

analysis was not conducted.

104

The mean duration of therapy for those who achieved microbiological cure was 23.6 days (SD=+/- 12.9), and for

105

those who did not was 17.9 days (SD= +/- 8.4), but the difference was not significant (p=0.08). Similarly, those

106

achieving clinical cure had a mean duration of therapy of 22.4 days (SD= +/- 12.3), compared with 16.9 days

107

(SD=+/- 7.2) for those who had no clinical cure (p = 0.219). ESBL status had no impact on outcomes in our

108

cohort (microbiological cure p=0.695, clinical cure p=0.663).

109

4. Discussion

110

In this study, the safety and efficacy of ertapenem in the OPAT setting were demonstrated for the treatment of

111

cUTIs. The overall clinical success rate among patients was 92%, while 3 (5%) patients discontinued therapy due

112

to adverse effects. A total of 52 (85%) had their original organisms eradicated (Table 3). None of the non-ESBL

113

organisms developed resistance following ertapenem therapy. Patients who had K. pneumoniae infection prior to

114

commencing therapy were less likely to achieve microbiological eradication. Indeed, the microbiological cure rate

115

in those with K. pneumoniae was (50%), and significantly contributed to the overall microbiological cure rate

116

(67%). Of those without microbiological eradication none were re-admitted in the subsequent 3 months for cUTI.

117

Our study was limited by its observational nature and the relatively small number of participants making subgroup

118

analysis difficult. Furthermore, it was a single-arm study with no comparator. The study did not look at outcomes

119

of cUTIs treated by other antimicrobials. Being an OPAT study, there was clearly a selection bias towards patients

120

who were well enough to continue therapy as outpatients, but the safety and efficacy of ertapenem has been

121

previously established in the inpatient setting [5, 13-15]. By following well-established microbiological definitions

122

[12], the study’s primary outcome was microbiological eradication, which may not reflect real life clinical

123

contexts, where a positive microbiology could indicate colonization rather than infection. This may have reflected

124

on the relatively prolonged mean duration of therapy, which was not associated with outcome, suggesting that

125

longer courses were not necessary.

126

The largest OPAT cohort prior to our study included 50 patients, but it was in a paediatric population[16].

127

Similarly, studies conducted in outpatient populations who received ertapenem included even smaller numbers[8-

128

10], with one study including women with simple cystitis. This study demonstrated that ertapenem is a good

129

alternative to broader-spectrum carbapenems in the treatment of cUTIs. As well as being safe and effective it has

130

the advantages of a narrower spectrum and lends itself to an OPAT setting being a once daily dosing.

131
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Table 1: Baseline characteristics of patients with cUTIs, (n=61) and their univariate analysis against
microbiological cure rates following therapy with ertapenem

Characteristics

Frequency

Microbiological

Microbiological

Odds

cure (%)

failure (%)

Ratio

95% CI

pvalue

(n=61)
(%)

Male (n [%])

37 (60.7)

70.2

29.7

1.15

0.73-1.83

0.584

Chinese (n [%])

38 (62.3)

68.4

31.6

1.17

0.39-3.46

1.0

Indian (n [%])

11 (18.0)

45.5

54.5

0.32

0.09-1.23

0.153*

Malay (n [%])

7 (11.5)

71.4

28.6

1.25

0.22-7.08

1.0

Other ethnicity

5 (8.2)

100

0

0.88

0.78-0.98

0.162

59 (+/-16)

59 (+/-15)

61 (+/-17)

N/A

N/A

N/A

>65 years (n [%])

35 (57.4)

88.6

11.4

1.17

0.56-2.42

0.651

K. pneumoniae

14 (22.9)

43

57

0.26

0.07-0.89

0.049*

ESBL detected

41 (67)

75.6

24.4

1.26

0.40-3.93

0.772

Pyelonephritis (n

24 (39.3)

75

25

1.83

0.58-5.7

0.405

11 (18)

64

36

0.82

0.21-3.22

0.78

6 (9.8)

83.3

16.7

2.64

0.29-24.2

0.351

(n [%])

Mean age (+/SD)

on intitial culture
(n[%])

[%])

Prostatitis (n
[%])

Urosepsis (n
[%])

Cystitis (n [%])

20 (32.8)

55

45

0.45

0.15-1.37

0.245

No. of days on

10 (+/-7.5)

10.5 (+/-7.4)

10.3 (+/-7.9)

N/A

N/A

0.835

No. of days on

22 (+/-

23.6 (+/-12.9)

17.9 (+/-8.4)

N/A

N/A

0.08

therapy (inpatient

11.8)

therapy in OPAT
(mean +/- SD)

& OPAT)
(mean+/-SD)

* entered into multivariate model

180

Table 2: Microbiological characteristics and outcomes of patients with complicated urinary tract infections
(n=61). Note: Patients with mixed E.coli and K. pneumoniae (n=3), M. morganii (n=2), and no significant
growth (n=1) are not included.

181

ESBL detected (%)

ESBL not detected (%)

Total (%)

E. coli

27

14

41

Clinical Cure

24 (89)

13 (93)

37 (90)

Microbiological Cure

21 (78)

10 (71)

31 (76)

K. pneumoniae

12

2

14

Clinical Cure

10 (83)

2 (100)

12 (86)

Microbiological Cure

6 (50)

0 (0)

6 (43)

Table 3: Clinical and microbiological outcomes (n=61)

Clinical Cure

Clinical Failure

Total

Microbiological cure

40 (65%)

1 (2%)

41 (67%)

Microbiological

9 (15%)

2 (3%)

11 (18%)

7 (11%)

2 (3%)

9 (15%)

56 (92%)

5 (8%)

61**

superinfection*

Microbiological
persistence

Total
*Those

who had a new micro-organism isolated at the end of therapy or on follow-up, **Including one

patient with pyelonephritis (no isolated micro-organism at diagnosis) but who had clinical cure and
clear urine culture following empiric treatment with ertapenem.
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